Performance of Vitek 2 for antimicrobial susceptibility testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints

Journal of Clinical Microbiology

Volumn 53, Issue 3, 2015, Pages 816-823

  Bobenchik, April M ^a   Deak, Eszter ^a   Hindler, Janet A ^b   Charlton, Carmen L ^a   Humphries, Romney M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; CARBAPENEM; CEFALOTIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANALYTICAL EQUIPMENT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CITROBACTER FREUNDII; CITROBACTER KOSERI; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROTEUS VULGARIS; PROVIDENCIA STUARTII; SERRATIA MARCESCENS; COMPARATIVE STUDY; DIAGNOSTIC ERROR; DRUG EFFECTS; EVALUATION STUDY; HUMAN; MICROBIAL SENSITIVITY TEST; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ENTEROBACTERIACEAE;

ANTI-BACTERIAL AGENTS; DIAGNOSTIC ERRORS; ENTEROBACTERIACEAE; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84923374128     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02697-14     Document Type: Article

References (16)

1. Doern CD, Dunne WM, Jr, Burnham CA. 2011. Detection of Klebsiella pneumoniae carbapenemase (KPC) production in non-Klebsiella pneumoniae Enterobacteriaceae isolates by use of the Phoenix, Vitek 2, and disk diffusion methods. J Clin Microbiol 49:1143-1147. http://dx.doi.org/10.1128/JCM.02163-10.
2. Lat A, Clock SA, Wu F, Whittier S, Della-Latta P, Fauntleroy K, Jenkins SG, Saiman L, Kubin CJ. 2011. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J Clin Microbiol 49:1795-1798. http://dx.doi.org/10.1128/JCM.02534-10.
3. Bulik CC, Fauntleroy KA, Jenkins SG, Abuali M, La Bombardi VJ, Nicolau DP, Kuti JL. 2010. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol 48:2402-2406. http://dx.doi.org/10.1128/JCM.00267-10.
4. Pitout JD, Le P, Church DL, Gregson DB, Laupland KB. 2008. Antimicrobial susceptibility of well-characterised multiresistant CTX-Mproducing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam. Int J Antimicrob Agents 32:333-338. http://dx.doi.org/10.1016/j.ijantimicag.2008.04.023.
5. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Pollett S, Miller S, Hindler J, Uslan D, Carvalho M, Humphries RM. 10 Sept 2014. Phenotypic and molecular characteristics of carbapenem resistant Enterobacteriaceae in a Los Angeles healthcare system, 2011 to 2013. J Clin Microbiol 52:4003-4009. http://dx.doi.org/10.1128/JCM.01397-14.
8. bioMérieux. 2013. VITEK 2 AST-GN69 product information. bioMérieux, Inc., Durham, NC.
9. bioMérieux. 2013. VITEK 2 AST-XN06 product information. bio-Mérieux, Inc., Durham, NC.
10. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Sharp SE, Clark RB. 2009. Cumitech 31A: verification and validation of procedures in the clinical microbiology laboratory. ASM Press, Washington, DC.
12. Bobenchik AM, Hindler JA, Giltner CL, Saeki S, Humphries RM. 2014. Performance of Vitek 2 for antimicrobial susceptibility testing of Staphylococcus spp. and Enterococcus spp. J Clin Microbiol 52:392-397. http://dx.doi.org/10.1128/JCM.02432-13.
13. Jang W, Park YJ, Park KG, Yu J. 2013. Evaluation of MicroScan Walk-Away and Vitek 2 for determination of the susceptibility of extendedspectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime. J Antimicrob Chemother 68:2282-2285. http://dx.doi.org/10.1093/jac/dkt172.
14. Espinar MJ, Rocha R, Ribeiro M, Gonçalves Rodrigues A, Pina-Vaz C. 2011. Extended-spectrum β-lactamases of Escherichia coli and Klebsiella pneumoniae screened by the Vitek 2 system. J Med Microbiol 60(Pt 6):756-760. http://dx.doi.org/10.1099/jmm.0.024075-0.
15. Pailhoriès H, Cassisa V, Lamoureux C, Chesnay A, Lebreton C, Lemarié C, Kempf M, Mahaza C, Joly-Guillou ML, Eveillard M. 2014. Discordance in the minimal inhibitory concentrations of ertapenem for Enterobacter cloacae: Vitek 2 system versus Etest and agar dilution methods. Int J Infect Dis 18:94-96. http://dx.doi.org/10.1016/j.ijid.2013.09.006.
16. Huang TD, Berhin C, Bogaerts P, Glupczynski Y. 2012. In vitro susceptibility of multidrug-resistant Enterobacteriaceae clinical isolates to tigecycline. J Antimicrob Chemother 67:2696-2699. http://dx.doi.org/10.1093/jac/dks288.